This is a demo store. No orders will be fulfilled.

KYA1797K - 10mM in DMSO, high purity , CAS No.1956356-56-1(DMSO)

    Grade & Purity:
  • 10mM in DMSO
In stock
Item Number
K408253
Grouped product items
SKU Size
Availability
Price Qty
K408253-1ml
1ml
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$237.90

Wnt/beta-catenin Inhibitors

View related series
Compound libraries (12325)

Basic Description

Synonyms 3-​Thiazolidinepropanoi​c acid, 5-​[[5-​(4-​nitrophenyl)​-​2-​furanyl]​methylene]​-​4-​oxo-​2-​thioxo-​, potassium salt (1:1)​, (5Z)​-
Specifications & Purity 10mM in DMSO
Biochemical and Physiological Mechanisms KYA1797K is a highly potent and selective Wnt/β-catenin inhibitor with IC50 of 0.75 µM (TOPflash assay).
Storage Temp Store at -80°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Product Description

Information

KYA1797K KYA1797K is a highly potent and selective Wnt/β-catenin inhibitor with IC50 of 0.75 µM (TOPflash assay).
In vitro

KYA1797K significantly decreases reporter activities for the Wnt/β-catenin and MAPK/ERK pathways but does not affect the reporter activities of other cancer-related pathways, such as the Notch and TGFβ pathways, thus, KYA1797K selectively regulates the Wnt/β-catenin and Ras/ERK pathways. KYA1797K enhances the β-catenin binding affinity of endogenous axin, GSK3β and β-TrCP. Interaction between APC and β-catenin is not enhanced by KYA1797K. It promotes the formation of the β-catenin destruction complex. KYA1797K degrades both β-catenin and Ras in these cells(CRC lines SW480, LoVo, DLD1 and HCT15) in a dose-dependent manner, cell proliferation is also suppressed by KYA1797K treatment. KYA1797K inhibits proliferation of CRC cells mainly via destabilization of β-catenin with additional Ras degradation. KYA1797K directly targeted axin and modulated conformation of the β-catenin destruction complex.

In vivo

KYA1797K administration by intraperitoneally injection(i.p.) (25 mg/kg) reduces both weight and volume of the tumor by 70% in mice carrying xenografted tumors from the D-MT cell line that harbors both APC and KRAS mutations. KYA1797K treatment significantly reduces levels of β-catenin and Ras proteins as well as Wnt/β-catenin and Ras signaling target. No change in the weight and no abnormalities in liver tissues of mice treated with KYA1797K. KYA1797K significantly reduces the subcellular localization of β-catenin in the nuclei and pan-Ras on the membrane of tumor cells. Thus, KYA1797K has anti-tumor effect.
Cell Data

cell lines:CHO cells expressing the h5-HT1B or h5-HT1D receptors

Concentrations:25 μM

Incubation Time:72 h

Powder Purity:≥99%

Names and Identifiers

Smiles [O-][N+](=O)C1=CC=C(C=C1)C2=CC=C(O2)\C=C3/SC(=S)N(CCC(=O)O[K])C3=O
Molecular Weight 442.51

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.